New hemophilia drug may last longer, reducing need for frequent shots
NCT ID NCT06579144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called efanesoctocog alfa in 24 adults with severe hemophilia A. Researchers compared how long it stays in the body versus two existing drugs. Participants received one dose of their usual drug, then later one dose of the new drug, with blood samples taken over several days. The goal was to see if the new drug lasts longer, which could mean fewer injections for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
efanesoctocog alfa (a longer-lasting clotting factor)
What this could lead to
If this drug lasts longer in the body, people with hemophilia A may need fewer infusions to prevent bleeding.
What could go wrong
This is a small, early-phase study in 24 people. It only measures drug levels, not actual bleeding prevention. The drug may not work better in real life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sobi Investigational Site
Sofia, Bulgaria
-
Sobi Investigational Site
Bonn, Germany
-
Sobi Investigational Site
Milan, Italy
-
Sobi Investigational Site
A Coruña, Spain
-
Sobi Investigational Site
Valencia, Spain
-
Sobi Investigational Site
Zaragoza, Spain
-
Sobi Investigational site
Frankfurt, Germany